Inferra AI / Company / NUTX
Nutex Health Inc.
NUTX · Health Care
Last earnings Aug 6, 2026
Key results
Total revenueytd
$455.8 million
htm EX-99.1 Document NUTEX HEALTH REPORTS JUNE 30, 2025 SECOND QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS Total revenue of $455.8 million for the first half of 2025 versus $143.5 million for the first half of 2024, an increase of 217.5% Net income attributable to Nutex Health Inc.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Net incomequarter
$3.5 million
The $3.5 million in net income includes non-cash stock-based compensation expense of $106.4 million, while the $0.7 million net loss includes no non-cash stock-based compensation expense.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Revenuequarter
217.5%
We are pleased to report 217.5% revenue growth, Adjusted EBITDA attributable to Nutex Health of $144.4 million, a 643.5% increase in gross profit and a record high cash balance of $96.7 million, highlighting the company's continued financial strength and solid fundamentals as we execute on our growth plan for 2025, stated Jon Bates, Chief Financial Officer of Nutex Health.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
AI analysis
Q2 2025 · reported Nov 18, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Net income | $3.5 million | — | — |
| Revenue | 217.5% | — | — |
Guidance · company-stated
No guidance located in the held release
Capital allocation
As of June 30, 2025, the Company had total assets of $841.0 million, including cash and cash equivalents of $96.7 million, and long-term debt, net of $20.5 million.
Share Repurchase Program On August 14, 2025, the Board of Directors authorized a stock repurchase program of up to $25.0 million of the Company s common stock over the next six months.
Company-stated claims
Forward-looking · increased 3100% · cash_flow
“Net income attributable to Nutex Health increased 3100% in the first six months of 2026 as compared to the same period in 2025, underscoring strong operating cash generation and execution of its planned growth strategy.”
EX-99 · Aug 6, 2026Event summary
NUTEX HEALTH REPORTS JUNE 30, 2025 SECOND QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
As of June 30, 2025, the Company had total assets of $841.0 million, including cash and cash equivalents of $96.7 million, and long-term debt, net of $20.5 million.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Share Repurchase Program On August 14, 2025, the Board of Directors authorized a stock repurchase program of up to $25.0 million of the Company s common stock over the next six months.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
The purpose of the share repurchase program is to increase shareholder value and offset dilution from the issuance of additional shares related to stock compensation obligations for under-construction and ramping hospitals.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Pursuant to the stock repurchase program, the Company may repurchase, from time to time, up to an aggregate of $25.0 million of the its outstanding shares of common stock, exclusive of any fees, commissions or other expenses related to such repurchases.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
The stock repurchase program permits the Company to repurchase shares of common stock at any time or from time to time at management s discretion in open market transactions made in accordance with the provisions of Rule 10b-18 and or Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, privately negotiated transactions or by other means in accordance with applicable securities laws.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
The timing of any repurchases and the number of shares repurchased are subject to the discretion of the Company and may be affected by various factors, including general market and economic conditions, the market price of the Company s common stock, the Company s earnings, financial condition, capital requirements and levels of indebtedness, legal requirements, and other factors that management may deem relevant.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Strategy & priorities
This document contains certain forward-looking statements with respect to our financial condition, results of operations and business, plans, objectives and strategies.
SEC original ↗Nutex Health Inc. — 10-Q Quarterly report10-QAug 6, 2026
These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate.
SEC original ↗Nutex Health Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
8 Forward-Looking Statements Certain statements and information included in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Act of 1995.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
SEC original ↗Nutex Health Inc. — Earnings release (8-K exhibit)EX-99Nov 18, 2025
Legal Proceedings 42 Item 1A.
SEC original ↗Nutex Health Inc. — 10-Q Quarterly report10-QAug 6, 2026
By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.
SEC original ↗Nutex Health Inc. — 10-Q Quarterly report10-QAug 6, 2026
Note 10 Commitments and Contingencies Litigation .
SEC original ↗Nutex Health Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q2 2026
- 8-KNUTX
Sep 11, 2026
- 8-KNUTX
Aug 31, 2026
- 8-KNUTX
Aug 24, 2026
- 8-KNUTX
Aug 13, 2026
- 10-QNUTX
Aug 6, 2026
- 8-KNUTX
Aug 6, 2026
- 8-KNUTX
Jul 21, 2026
- Q1 2026
- 10-QNUTX
Apr 30, 2026
- 8-KNUTX
Apr 30, 2026
- 8-KNUTX
Apr 23, 2026
- Q4 2025
- 10-KNUTX
Mar 5, 2026
- 8-KNUTX
Mar 5, 2026
- Q3 2025
- 8-KNUTX
Nov 24, 2025
- 10-QNUTX
Nov 19, 2025
- 8-KNUTX
Nov 19, 2025
- 8-KNUTX
Nov 18, 2025
- 8-KNUTX
Nov 18, 2025
- 10-QNUTX
Nov 18, 2025
- 8-KNUTX
Nov 18, 2025
- 8-KNUTX
Oct 20, 2025
- EX-99NUTX
Oct 20, 2025
- Q2 2025
- 8-KNUTX
Sep 22, 2025
- 8-KNUTX
Sep 10, 2025
- 8-KNUTX
Sep 4, 2025
- 8-KNUTX
Aug 25, 2025
- 8-KNUTX
Aug 21, 2025
- 8-KNUTX
Aug 14, 2025
- 8-KNUTX
Jul 16, 2025
- 8-KNUTX
Jul 11, 2025
- Q1 2025
- 8-KNUTX
May 21, 2025
- 8-KNUTX
May 13, 2025
Earnings releases
11 documentsPresentations
0 documentsNo presentations for Nutex Health Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Nutex Health Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.